|By PR Newswire||
|February 26, 2014 03:13 PM EST||
DUBLIN, February 26, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/khhjl8/erectile) has announced the addition of the "Erectile Dysfunction Drugs Market - Forecast to 2019" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
The erectile dysfunction drugs market is expected to witness a decline across the globe, by the end of the forecast period, i.e. by 2019, due to patent expiration of the key revenue generating drug Viagra outside the U.S. in 2013. In addition, Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG are also scheduled to lose their patent exclusivities during the forecast period. The loss of patent and marketing exclusivity will lead to a drastic reduction in revenues and in turn provide an opportunity to generic manufacturers to launch their own versions of these brands. Moreover, low success rate of novel drug formulations owing to weak pipeline development will also account for the downturn of the overall erectile dysfunction drugs market.
Pfizer's Viagra was the largest revenue generator in 2012, in the total market, owing to its foremost presence in the pharmaceutical market for erectile dysfunction treatment. Viagra has maintained its blockbuster status till date, recording billion dollar sales every year for Pfizer, Inc. The primary competitors on the market for Viagra are Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG.
Geographically, North America dominated the global erectile dysfunction drugs market and is expected to continue to lead in terms of revenue generation throughout the forecast period. North America is considered as the most lucrative market for erectile dysfunction drugs owing to the presence of blockbuster drugs Viagra and Cialis in the U.S. market through 2019. The North American market for erectile dysfunction drugs was valued at USD 2,098.4 million in the year 2012.
However, loss of patent exclusivities for Cialis (tadalafil) and Levitra/Staxyn (vardenafil) within the forecast period are expected to hamper market growth, though to a lesser extent. Factors such as increased market consolidation (due to influx of generics and weak pipeline development), cost containment measures coupled with introduction of cheaper products will result in rapid adoption of these drugs in the emerging markets. The leading players in the market for branded erectile dysfunction drugs are Pfizer, Inc., Eli Lilly & Co., Bayer AG, Dong-A Pharmaceutical Co. Ltd and Vivus, Inc.
Key Topics Covered:
2 Executive Summary
3 Market Overview
4 Global Erectile Dysfunction Drugs Market Revenue, By Brand, 2011-2019 (USD Million)
5 Global Erectile Dysfunction Drugs Market, Pipeline Analysis
6 Global Erectile Dysfunction Drugs Market, By Geography
7 Competitive Landscape
9 Company Profiles
- Apricus Biosciences, Inc
- Bayer AG
- Cristalia Produtos Quimicos Farmaceuticos Ltda
- Dong-A Pharmaceutical Co Ltd
- Eli Lilly And Company
- Meda Pharmaceuticals, Inc
- Pfizer, Inc
- SK Chemicals Co Ltd
- Vivus, Inc
For more information visit http://www.researchandmarkets.com/research/khhjl8/erectile
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets